Macitentan Patent Expiration

Macitentan is used for treating pulmonary arterial hypertension. It was first introduced by Actelion Pharmaceuticals Us Inc in its drug Opsumit on Oct 18, 2013. 5 different companies have introduced drugs containing Macitentan.


Macitentan Patents

Given below is the list of patents protecting Macitentan, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Opsumit US8268847 Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor Apr 18, 2029 Actelion
Opsumit US8367685 Stable pharmaceutical compositions comprising a pyrimidine-sulfamide Oct 04, 2028 Actelion
Opsumit US9265762 Stable pharmaceutical compositions comprising a pyrimidine-sulfamide May 29, 2027 Actelion
Opsumit US10946015 Stable pharmaceutical compositions comprising a pyrimidine-sulfamide Sep 11, 2026 Actelion
Opsumit US7094781 Sulfamides and their use as endothelin receptor antagonists Dec 05, 2025 Actelion



Macitentan's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Macitentan Generics

Several generic applications have been filed for Macitentan. The first generic version for Macitentan was by Zydus Lifesciences Global Fze and was approved on Apr 6, 2021. And the latest generic version is by Torrent Pharmaceuticals Ltd and was approved on Aug 5, 2024.

Given below is the list of companies who have filed for Macitentan generic.


1. APOTEX

Apotex Inc has filed for 1 generic for Macitentan. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG tablet Discontinued ORAL N/A Jan 9, 2024


2. AUROBINDO PHARMA LTD

Aurobindo Pharma Ltd has filed for 1 generic for Macitentan. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG tablet Discontinued ORAL N/A Apr 18, 2023


3. TORRENT

Torrent Pharmaceuticals Ltd has filed for 1 generic for Macitentan. Given below are the details of the strengths of this generic introduced by Torrent.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG tablet Discontinued ORAL N/A Aug 5, 2024


4. ZYDUS LIFESCIENCES

Zydus Lifesciences Global Fze has filed for 1 generic for Macitentan. Given below are the details of the strengths of this generic introduced by Zydus Lifesciences.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG tablet Discontinued ORAL N/A Apr 6, 2021